S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Closing prices for crude oil, gold and other commodities
A gold storm is coming… (Ad)
MarketBeat Week in Review – 1/30 - 2/3
Ford, Starbucks fall; Clorox, Gilead Sciences rise
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Skull found in '97 in remote Alaska belongs to New York man
How major US stock indexes fared Friday 2/3/2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Jury: Musk didn't defraud investors with 2018 Tesla tweets
Treasury makes more electric SUVs eligible for tax credits
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Closing prices for crude oil, gold and other commodities
A gold storm is coming… (Ad)
MarketBeat Week in Review – 1/30 - 2/3
Ford, Starbucks fall; Clorox, Gilead Sciences rise
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Skull found in '97 in remote Alaska belongs to New York man
How major US stock indexes fared Friday 2/3/2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Jury: Musk didn't defraud investors with 2018 Tesla tweets
Treasury makes more electric SUVs eligible for tax credits
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Closing prices for crude oil, gold and other commodities
A gold storm is coming… (Ad)
MarketBeat Week in Review – 1/30 - 2/3
Ford, Starbucks fall; Clorox, Gilead Sciences rise
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Skull found in '97 in remote Alaska belongs to New York man
How major US stock indexes fared Friday 2/3/2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Jury: Musk didn't defraud investors with 2018 Tesla tweets
Treasury makes more electric SUVs eligible for tax credits
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Closing prices for crude oil, gold and other commodities
A gold storm is coming… (Ad)
MarketBeat Week in Review – 1/30 - 2/3
Ford, Starbucks fall; Clorox, Gilead Sciences rise
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Skull found in '97 in remote Alaska belongs to New York man
How major US stock indexes fared Friday 2/3/2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Jury: Musk didn't defraud investors with 2018 Tesla tweets
Treasury makes more electric SUVs eligible for tax credits
NASDAQ:VXRT

Vaxart - VXRT Stock Forecast, Price & News

$1.08
-0.02 (-1.82%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.07
▼
$1.13
50-Day Range
$0.75
▼
$1.30
52-Week Range
$0.73
▼
$5.43
Volume
1.93 million shs
Average Volume
1.76 million shs
Market Capitalization
$141.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75

Vaxart MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
339.8% Upside
$4.75 Price Target
Short Interest
Bearish
16.94% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$15,200 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.84) to ($0.99) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.86 out of 5 stars

Medical Sector

697th out of 1,028 stocks

Biological Products, Except Diagnostic Industry

112th out of 168 stocks

See Top Rated MarketRank™ Stocks Here
VXRT stock logo

About Vaxart (NASDAQ:VXRT) Stock

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Receive VXRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter.

VXRT Stock News Headlines

December 19, 2022 | finance.yahoo.com
Vaxart Names Phillip Lee as Chief Financial Officer
December 1, 2022 | finance.yahoo.com
Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers
February 4, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
December 1, 2022 | finance.yahoo.com
Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers
November 22, 2022 | finance.yahoo.com
Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29
November 11, 2022 | finance.yahoo.com
Vaxart Third Quarter 2022 Earnings: US$0.23 loss per share (vs US$0.14 loss in 3Q 2021)
November 8, 2022 | finance.yahoo.com
Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results
November 8, 2022 | finance.yahoo.com
VAXART, INC. (VXRT) Reports Q3 Loss, Misses Revenue Estimates
February 4, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
November 1, 2022 | finance.yahoo.com
VAXART, INC. (VXRT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
October 20, 2022 | globenewswire.com
Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8 - GlobeNewswire
October 20, 2022 | finance.yahoo.com
Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8
October 10, 2022 | globenewswire.com
Vaxart to Present at World Vaccine Congress Europe 2022 on October 13 - GlobeNewswire
October 10, 2022 | finance.yahoo.com
Vaxart to Present at World Vaccine Congress Europe 2022 on October 13
October 4, 2022 | nasdaq.com
2 Struggling Stocks to Avoid Right Now - Nasdaq
October 4, 2022 | fool.com
2 Struggling Stocks to Avoid Right Now - The Motley Fool
September 19, 2022 | benzinga.com
Why Vaxart Shares Are Falling - Vaxart (NASDAQ:VXRT) - Benzinga
September 9, 2022 | seekingalpha.com
Vaxart Stock: Market Still Isn't Buying Oral Vaccine Thesis (NASDAQ:VXRT) - Seeking Alpha
September 7, 2022 | finance.yahoo.com
Vaxart to Present at the H.C. Wainwright 24th Annual Global Investment Conference - Yahoo Finance
September 7, 2022 | benzinga.com
(VXRT) – Vaxart to Present at the H.C. Wainwright 24th Annual Global Investment Conference - Benzinga
September 7, 2022 | finance.yahoo.com
Vaxart to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 3, 2022 | seekingalpha.com
Vaxart stock rises as COVID pill vaccine shows response, safety in trial - Seeking Alpha
September 2, 2022 | finance.yahoo.com
Vaxart Names Biotech Veteran Ray Stapleton Chief Technology Officer - Yahoo Finance
September 1, 2022 | investorplace.com
What Is Going on With Vaxart (VXRT) Stock Today?
September 1, 2022 | investorplace.com
What Is Going on With Vaxart (VXRT) Stock Today? - InvestorPlace
September 1, 2022 | globenewswire.com
Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate - GlobeNewswire
September 1, 2022 | finance.yahoo.com
Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate
See More Headlines
Receive VXRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter.

VXRT Company Calendar

Last Earnings
11/08/2022
Today
2/04/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VXRT
Previous Symbol
NASDAQ:NABI
CUSIP
N/A
CIK
72444
Web
www.vaxart.com
Phone
(650) 550-3500
Fax
650-871-8580
Employees
110
Year Founded
2004

Price Target and Rating

Average Stock Price Forecast
$4.75
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+339.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.83)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-70,470,000.00
Net Margins
N/A
Pretax Margin
-65,745.28%
Return on Equity
-67.56%
Return on Assets
-53.76%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.54
Quick Ratio
5.54

Sales & Book Value

Annual Sales
$890,000.00
Price / Sales
159.27
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.49 per share
Price / Book
0.72

Miscellaneous

Outstanding Shares
131,250,000
Free Float
127,574,000
Market Cap
$141.75 million
Optionable
Not Optionable
Beta
0.80

Social Links


Key Executives

  • Andrei Floroiu
    President, Chief Executive Officer & Director
  • Phillip Eric Lee
    Chief Financial Officer
  • Sean N. TuckerSean N. Tucker
    Chief Scientific Officer & Senior Vice President
  • James F. Cummings
    Chief Medical Officer
  • Raymond D. Stapleton
    Chief Technology Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













VXRT Stock - Frequently Asked Questions

Should I buy or sell Vaxart stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VXRT shares.
View VXRT analyst ratings or view top-rated stocks.

What is Vaxart's stock price forecast for 2023?

3 Wall Street research analysts have issued twelve-month price targets for Vaxart's stock. Their VXRT share price forecasts range from $1.50 to $8.00. On average, they expect the company's stock price to reach $4.75 in the next year. This suggests a possible upside of 339.8% from the stock's current price.
View analysts price targets for VXRT or view top-rated stocks among Wall Street analysts.

How have VXRT shares performed in 2023?

Vaxart's stock was trading at $0.9609 at the beginning of 2023. Since then, VXRT stock has increased by 12.4% and is now trading at $1.08.
View the best growth stocks for 2023 here.

When is Vaxart's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our VXRT earnings forecast.

How were Vaxart's earnings last quarter?

Vaxart, Inc. (NASDAQ:VXRT) posted its earnings results on Tuesday, November, 8th. The biotechnology company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.01.

When did Vaxart's stock split?

Vaxart's stock reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

What other stocks do shareholders of Vaxart own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novavax (NVAX), Organigram (OGI) and Novan (NOVN).

What is Vaxart's stock symbol?

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Who are Vaxart's major shareholders?

Vaxart's stock is owned by many different institutional and retail investors. Top institutional investors include Private Portfolio Partners LLC (0.09%), SG Americas Securities LLC (0.04%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Armistice Capital, Llc, Fuad Ahmad, Margaret Echerd, Robert A Yedid, Sean Tucker, Todd C Davis, W Mark Watson and Wouter Latour.
View institutional ownership trends.

How do I buy shares of Vaxart?

Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaxart's stock price today?

One share of VXRT stock can currently be purchased for approximately $1.08.

How much money does Vaxart make?

Vaxart (NASDAQ:VXRT) has a market capitalization of $141.75 million and generates $890,000.00 in revenue each year. The biotechnology company earns $-70,470,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis.

How many employees does Vaxart have?

The company employs 110 workers across the globe.

How can I contact Vaxart?

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The official website for the company is www.vaxart.com. The biotechnology company can be reached via phone at (650) 550-3500, via email at ir@vaxart.com, or via fax at 650-871-8580.

This page (NASDAQ:VXRT) was last updated on 2/4/2023 by MarketBeat.com Staff